Nuwellis (NUWE) announced the presentation of new real-world data from New York City’s Lenox Hill Hospital at the 2025 American Society of Nephrology, ASN, Kidney Week, reinforcing the versatility of Aquadex ultrafiltration therapy in patients with acute kidney injury, AKI, and complex fluid management needs. The retrospective analysis, titled “Diversifying Aquapheresis Applications in Critical Care: Nephrology-Led Institutional Experience,” reviewed 69 cases treated with Aquadex between 2018 and 2024. The study demonstrated effective and predictable fluid removal in patients with multiple underlying conditions-ranging from oliguric AKI and post-cardiac-surgery volume overload to pre-operative optimization in end-stage renal disease. The analysis found that patients had an average of 6.4 liters of ultrafiltrate removed over a mean duration of 78 hours, with stable hemodynamics even among those on vasopressor support.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUWE:
- Nuwellis says U.S. children’s hospital initiates Aquadex Ultrafiltration Program
- Nuwellis Reports Q3 2025 Results and Strategic Advances
- Nuwellis reports Q3 EPS 56c
- Nuwellis receives notice of allowance for U.S. patent on Vivian system
- Nuwellis’ REVERSE-HF Study: A Potential Game-Changer in Heart Failure Treatment